“Reta” is online forum shorthand for retatrutide, an investigational obesity and metabolic medication being developed by Eli Lilly and Company. It is currently in Phase 3 clinical trials, has not received approval from the U.S. Food and Drug Administration (FDA) or global regulatory bodies, and cannot be legitimately prescribed or dispensed by a pharmacy.

Where the Nickname Came From

The moniker “reta” emerged across online communities—including Reddit, Discord, and peptide research forums—as a shorthand tag. It follows an established naming convention used in grey-market communities and patient discussion groups:

• Sema: Semaglutide (active ingredient in Ozempic and Wegovy)
• Tirz: Tirzepatide (active ingredient in Mounjaro and Zepbound)
• Reta: Retatrutide (investigational triple agonist, code name LY3437943)

Grey-Market Vocabulary Guide

• GLP-1 (Glucagon-Like Peptide-1): An incretin hormone that stimulates insulin secretion, slows gastric emptying, and signals fullness to the brain.
• GIP (Glucose-Dependent Insulinotropic Polypeptide): A second incretin hormone that enhances insulin secretion and influences lipid metabolism.
• Glucagon: A hormone that raises blood glucose levels and increases energy expenditure.
• Triple Agonist: A single molecule designed to simultaneously bind to and activate three distinct hormone receptors (GLP-1, GIP, and glucagon).
• Titration: The clinical process of gradually escalating a drug’s dose over weeks or months to build tolerance and minimize side effects.
• Stacking: The unauthorized practice of combining multiple metabolic peptides or compounds simultaneously.

What Retatrutide Actually Is

Retatrutide is a single synthetic peptide engineered to activate three metabolic hormone pathways simultaneously. To understand its structural role, it helps to view it alongside preceding metabolic therapies:

• Semaglutide (Single Agonist): Targets GLP-1 receptors exclusively.
• Tirzepatide (Dual Agonist): Targets both GLP-1 and GIP receptors.
• Retatrutide (Triple Agonist): Targets GLP-1, GIP, and Glucagon receptors.

While GLP-1 and GIP activation primarily lower appetite, slow gastric emptying, and improve glycemic control, the addition of glucagon receptor agonism is the key differentiator. Glucagon signaling acts directly on the liver and adipose tissue to increase basal metabolic rate and energy expenditure.

In simple terms: GLP-1 and GIP reduce energy input (calories consumed), while glucagon increases energy output (calories burned).

What the Phase 3 Trial Data Showed

Data from Eli Lilly’s clinical trial program demonstrate weight loss and glycemic efficacy across various patient populations:

Trial Name	Target Population	Key Efficacy Results by Dose
TRIUMPH-1	Adults with obesity or overweight (without diabetes)	Up to 30.3% average weight loss at higher doses over extended treatment.
TRIUMPH-2	Adults with type 2 diabetes and obesity/overweight	Average weight loss at 80 weeks: 12.7% (4 mg), 19.1% (9 mg), and 20.8% (12 mg).
TRIUMPH-3	Adults with severe obesity (BMI ≥ 35) and cardiovascular disease	Average weight loss at 80 weeks: 21.6% (9 mg) and 22.6% (12 mg).

Source: Data reported in official Eli Lilly and Company clinical updates and trial publications.

Side Effects Reported in the Trials

Clinical safety data indicate that retatrutide’s side effect profile is similar to established GLP-1 and dual-GIP/GLP-1 receptor agonists, with gastrointestinal symptoms representing the vast majority of adverse events:

• Diarrhea: Reported in 27% to 34% of retatrutide participants (compared to 13% on placebo).
• Nausea: Reported in 14% to 28% of retatrutide participants (compared to 8% on placebo).
• Constipation: Reported in 14% to 17% of retatrutide participants (compared to 9% on placebo).
• Decreased Appetite: A primary pharmacologic effect, frequently reported as a primary side effect.
• Cardiac Effects: Transient increases in heart rate were observed in Phase 2 and Phase 3 trials, peaking around weeks 20 to 24 before declining.

Gastrointestinal side effects were most prominent during the initial dose-escalation phase and generally decreased as treatment continued.

Where It Stands Right Now

Retatrutide remains an unapproved investigational compound. It is not available at commercial pharmacies, cannot be prescribed by physicians, and has not completed all regulatory reviews.

According to official guidance from Eli Lilly and Company, the company plans to submit a Biologics License Application (BLA) to the U.S. FDA in Q1 2027. Assuming a standard regulatory review timeline, commercial availability would not occur until later that year at the earliest.

So What Are People Actually Buying?

Because retatrutide is not commercially manufactured or approved for human use, any product currently sold online under the label “reta,” “retatrutide,” or “research peptide” originates from unregulated chemical synthesis sources.

These products are unverified in identity, purity, and concentration. Independent testing of grey-market chemical samples frequently reveals dosing inconsistencies, heavy metal contamination, endotoxins, and mislabeled structural analogs.

Frequently Asked Questions

Is “reta” legal to buy?

Retatrutide is an unapproved pharmaceutical compound. Selling or distributing it for human consumption outside authorized clinical trials violates federal law and FDA regulations. Chemical supply companies sometimes sell it tagged “for research use only,” but purchasing these substances for personal administration carries significant legal and medical risks.

Is retatrutide the same thing as Mounjaro or Zepbound?

No. Mounjaro and Zepbound are brand names for tirzepatide, a dual GIP/GLP-1 receptor agonist approved by the FDA. Retatrutide is a different, unapproved molecule that adds a third mechanism: glucagon receptor agonism.

When will retatrutide be available?

Eli Lilly plans to submit its FDA filing in Q1 2027. If approved, market launch would follow regulatory review, likely mid-to-late 2027.

How is retatrutide different from tirzepatide?

Tirzepatide targets two receptors (GIP and GLP-1). Retatrutide targets three (GIP, GLP-1, and glucagon). The addition of glucagon activity is designed to increase energy expenditure in addition to reducing appetite.